Recent progress in the treatment of uveitic macular edema. (3rd September 2019)

• Record Type: Journal Article
• Authors: Adán, Alfredo; Moll-Udina, Aina; Alba-Linero, Carmen; Figueroa-Vercellino, Juan Pablo; Llorenç, Victor
• Is Part Of: Expert review of ophthalmology. Volume 14:Number 4/5(2019)
• Page Start: 227
• Page End: 236
• Publication Date: 2019-09-03
• Subjects: Uveitic macular edema -- non-infectious uveitis -- dexamethasone intravitreal implant -- fluocinolone acetonide intravitreal implant -- anti-tumor necrosis factor alpha -- anti-interleukin 6 -- pars plana vitrectomy -- corticosteroids; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1080/17469899.2019.1644168
• Languages: English
• ISSNs: 1746-9899

Abstract

ABSTRACT: Introduction : Macular edema (ME) is defined as a thickening of the macular area, which results from a breakdown of the outer and/or inner blood-retina barrier. It is usually accompanied by quantity and quality loss of central vision. Uveitic macular edema (UME) is a leading cause of visual loss due to macular edema chronification. A number of treatment options are available for UME including periocular and intravitreal corticosteroids, immunosuppressants and biological agents. Pars plana vitrectomy also plays a role in refractory patients. Areas covered : We herein provide a summary of current options to treat UME, highlighting strengths and weaknesses on the basis of available literature and self-experience. Expert opinion : Visual prognosis in uveitis has improved as treatment of macular edema has done in the last decade. Corticosteroid slow-release intravitreal implants as well as anti-TNF and anti-IL-6 biologic drugs have been the cornerstone of these medical advances.